Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly
associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs …

Schizophrenia is a chronic neuropsychiatric syndrome that significantly impacts daily
function and quality of life. All of the available guidelines suggest a combined treatment …

Bipolar depression remains a clinical challenge with a quarter of patients failing to respond
to initial conventional treatments. Although ketamine has been extensively studied in …

Because there are a limited number of animal models for psychiatric diseases that can be
extrapolated to humans, drug repurposing has been actively pursued. This study was aimed …

Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic-inflammatory disease
associated with poor outcomes and decreased quality of life. NAFLD is overrepresented in …

A green, environmentally friendly, quick, sensitive, cost-effective, stability-indicating, and
analyst-friendly UPLC method for determining the content of Olanzapine and Samidorphan …

Background and Objective: United States Food and Drug Administration (USFDA) recently
approved a novel combination of olanzapine-samidorphan (OLZSAM) for managing …

Purpose This meta-analysis intended to evaluate the safety and metabolic effects of the
combination of olanzapine (OLZ) and samidorphan (SAM) in the treatment of schizophrenia …

Introduction Effective side effects management present a challenge in antipsychotic
treatment with second-generation antipsychotics (SGAs). In recent years, most of the …

Introduction Developing novel antipsychotic mechanisms of action and repurposing
established compounds for the treatment of schizophrenia is of utmost importance to …